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Mid-term results with laser atherectomy in the
treatment of infrainguinal occlusive disease
Michael C. Stoner, MD, Dorian J. deFreitas, MD, Sachin V. Phade, MD, Frank M. Parker, DO,
William M. Bogey, MD, and Steve Powell, MD, Greenville, NC
Background: Laser atherectomy offers a potential intervention for multivessel infrainguinal disease in patients with poor
revascularization options. Despite promising early results reported in the literature, the proper patient population who
might benefit from laser atherectomy has yet to be determined.
Methods: From July 2004 to June 2006, patients undergoing laser atherectomy were retrospectively reviewed and assessed
for comorbidities, operative and follow-up variables potentially associated with the end points of nondefinitive therapy,
and limb salvage.
Results: During the study period, 40 patients (21 women, 19 men) underwent laser atherectomy, and the average
follow-up was 461  49 days (range, 17 to 1050 days). Their average age was 68  2 years (range, 43 to 93 years). The
indication for laser atherectomy was critical limb ischemia in 26 (65%) and lower limb claudication in 11 (35%). A total
of 47 lesions were treated in the following arterial segments: 34 femoropopliteal and 13 infrapopliteal. Femoropopliteal
distribution by the Trans-Atlantic Society Classification (TASC) was A in 3, B in 17, C in 10, D in 4, and infrapopliteal
lesions distribution was A in 1, B in 3, C in 4, and D in 5. Adjunctive angioplasty was used in 75% of cases. The overall
technical success rate (<50% residual stenosis) was 88%. Laser atherectomy–based treatment was the definitive therapy for
23 patients (58%), and the overall 12-month primary patency was 44%. The limb salvage rate at 12 months in 26 patients
with critical limb ischemia was 55%. Renal failure was a risk factor for amputation (P< .001) and failed primary patency
(P < .05), type 2 diabetes mellitus was a risk factor for amputation (P < .05), and poor tibial runoff was associated with
failed primary patency and amputation (P < .05). Outcome was associated with the number of patent infrapopliteal
runoff vessels.
Conclusion: These data demonstrate that laser atherectomy can be used with high initial technical success rate. Chronic
renal failure and diabetes are risk factors for a negative outcome. Poor results in patients with diabetes and renal failure
necessitate careful case selection in this subgroup, in which laser atherectomy is less likely to provide a definitive
revascularization result or limb salvage. (J Vasc Surg 2007;46:289-95.)Laser atherectomy, also known as laser-assisted balloon
angioplasty, was initially introduced in the 1980s for the
treatment of peripheral arterial disease.1 Neodymium:YAG
lasers successfully delivered sufficient energy to debulk and
successfully cross long occlusions and stenosis.2 Unfortu-
nately, a great deal of thermal energy was produced, leading
to vessel wall damage. The resulting injury led to a high
incidence of vessel thrombosis, spasm, and subsequent
revascularization failure.
The excimer laser overcomes several technical short-
comings of earlier laser-based therapies and has been intro-
duced as a vascular atherectomy device. Lower energy
photons cause less thermal damage, and more flexible
catheters result in less vessel wall perforation. Laser atherec-
tomy is a potential option for patients that are a high
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doi:10.1016/j.jvs.2007.04.019surgical risk because of poor underlying physiology or
complex lesion anatomy. Short-term outcomes from mul-
ticenter trials cite patency rates as high as 93% at 6 months
in patients with critical limb ischemia.3
Despite this, skepticism exists about the long-term
results of laser atherectomy and its place in the ever-
growing list of endovascular therapies. The primary trials
supporting the use of the excimer laser were industry-
sponsored and subject to significant critique by the surgical
community.3,4 The purpose of this study was to examine
contemporary outcomes associated with laser-assisted
lower extremity revascularization outside of the confines of
a clinical trial.
METHODS
Patient selection and data collection. From July
2004 through June 2006, all patients undergoing catheter-
based atherectomy of the infrainguinal arterial circulation
were identified in a prospectively maintained computerized
database (Common Procedural Codes 35495 and 45493),
and all laser cases were then selected. The decision to use
laser-assisted revascularization was based on clinical evalu-
ation, anatomic factors, and the attending surgeon’s pref-
erence. The study was approved by the University and
Medical Center Institutional Review Board of the East
Carolina University.
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come variables were collected from the computerized pa-
tient care records. Basic demographic data were recorded,
omitting patient identifying information. The indication
for revascularization was classified by the criteria of Ruth-
erford et al.5 Patient comorbidities were defined as:
● diabetes mellitus: medical treatment for diabetes;
● hypertension: medical treatment for hypertension;
● hyperlipidemia: medical treatment of dyslipidemia or
total cholesterol 200 mg/dL;
● tobacco use: recorded as both lifetime tobacco use and
current use;
● coronary disease: medical therapy for coronary vascular
disease or prior coronary revascularization;
● renal insufficiency: serum creatinine1.5mg/dL; and
● dialysis: chronic renal replacement therapy.
Perioperative medical management was noted and the
following variables were dichotomized: aspirin use, clopi-
dogrel (Plavix, Sanofi-Aventis, Bridgewayer, NJ) use, war-
farin (Coumadin, Bristol-Myers Squibb, Princeton, NJ)
use, and lipid-lowering therapy.
Critical limb ischemia (CLI) was defined as a Ruther-
ford category 3.
Anatomic and morphologic characteristics were ob-
tained by review of the archived images from the individual
cases. Calibrated angiography was used to determine lesion
lengths. The segment of intervention (femoropopliteal or
infrapopliteal) was noted along with the number of patent
tibial runoff vessels to the foot. These data were used to
assign the target lesion with a TransAtlantic Inter-Society
Consensus (TASC) classification (Appendix, online only).6
Adjunctive endovascular procedures (angioplasty or stent-
ing) and open procedures were documented.
Procedure. Monitored anesthetic care was used in
most cases. Selective arteriography was obtained through
contralateral retrograde femoral access or ipsilateral ante-
grade femoral access by using a 5F or 6F system. After
localizing the index lesion, an attempt was made to cross
the lesion with standard guidewire technique. This typically
involved the use of a hydrophilic 0.035-inch guidewire or
0.014-inch/0.018-inch wire with a shapeable tip, avoiding
subintimal passage. For lesions resistant to guidewire tra-
versing, the laser “step-by-step” technique was used.7 In
brief, the step-by-step technique involves using brief appli-
cations of laser energy to allow serial advancement of the
catheter and guidewire through the lesion.
Atherectomy was undertaken using the CLiRpath
308-nm wavelength excimer laser system (Spectranetics,
Colorado Springs, Colo). The index lesion was debulked,
and adjunctive angioplasty or stenting was then undertaken
at the discretion of the operating surgeon. Stenting was
used in a selective fashion only in flow-limiting dissections
and recalcitrant lesions.
Technical success was defined as the ability to cross the
target lesion with a wire, and achieve a residual stenosis
50% in all lesions treated, which is a definition derived
from the Laser Angioplasty to treat Critical Limb Ischemia(LACI) trial.3 Hemodynamic success was defined at an
increase in ankle-brachial index (ABI) 0.1 or increase in
plethysmographic tracing of 5 mm, or both.
All patients underwent risk-factor examination and
modification in conjunction with their primary care pro-
vider. All attempts were made to optimize lipid profile,
glycemic control, and hypertension management.
Procedural complications. Major and minor adverse
events were recorded from the medical record. These in-
cluded patient mortality from any cause, vessel damage
from the catheter (dissection or perforation), access site
complications, and any other untoward event.
Long-term end points. Primary patency and limb
salvage were the principle end points in this study. Patency
was determined by the guidelines of Rutherford et al and
used routine physiologic examinations in those patients
without a palpable pulse.5 Duplex ultrasound surveillance
was not used in these patients. Deterioration in clinical
status or hemodynamics prompted further imaging. Failure
of limb salvage was defined as amajor amputation ipsilateral
to the target lesion. Total follow-up time was recorded for
each patient as well as the time to failed primary patency or
amputation, where appropriate.
Statistical analysis. Patient demographic, comorbid-
ity, medical therapy, and anatomic characteristic variables
were compared for each long-term outcome (primary pa-
tency and limb salvage in critical limb ischemia cases).
Categoric variables were analyzed using 2 with the Fisher
exact test as appropriate. Continuous variables were ana-
lyzed using the Student t test and are presented as mean 
standard error. A P  .05 was considered significant for all
statistical analysis. Kaplan-Meier life tables were created for
each significant variable with respect to the long-term
outcomes. The analysis was generated using SAS 9.1 soft-
ware (SAS Institute Inc, Cary, NC).
RESULTS
During the 24-month study period, 40 patients under-
went revascularization with laser atherectomy (Table I).
Most of these patients had rest pain or tissue loss as an
indication for revascularization. Hypertension was nearly
ubiquitous in the study population, and diabetes mellitus,
hyperlipidemia, and tobacco abuse were present in more
than half the patients. Most patients were maintained on
antiplatelet therapy in the perioperative period. During the
same time period, an additional 197 endovascular femoro-
popliteal or femoropopliteal with tibial interventions were
performed. The use of the laser catheter was at the discre-
tion of the attending surgeon and reserved for cases when a
guidewire could not be readily passed through a target
lesion into the distal circulation.
A total of 47 lesions were treated in these 40 patients,
and 34 were femoropopliteal arterial distribution (Table
II). TASC C or D lesions made up 41% of the femoropop-
liteal lesions and 69% of the infrapopliteal lesions. Adjunc-
tive angioplasty was used in 75% of the lesions, and 13%
required selective stenting. The initial technical success rate
was 88%, with a total major and minor adverse event rate of
*Categoric data are presented as number and percentage; continuous data as
mean  standard error (range).
minal angioplasty.
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75% of cases, with at least a 0.1 increase in ABI or 5 mm
improvement in pulse volume recording tracing. A guide-
wire was placed distal to the target lesion in all of the cases.
The 30-day adverse event rate was 33%, with two
deaths in this time period (Table III); neither was related to
the revascularization procedure. All other complications
were managed conservatively, and no emergency proce-
dures were required.
During the mean follow-up of 461  49 days, laser-
assisted revascularization was a definitive mode of revascu-
larization (remained primarily patent) in 23 of 40 total
cases (Table IV). Limb salvage was achieved in 19 of 26
cases of CLI (4 above knee amputations, 3 below knee
amputations). There was no limb loss in patients with
severe claudication. The CLI population had a higher
incidence of diabetes, renal insufficiency, and dialysis de-
pendence compared with the total group. CLI with diabe-
tes and renal insufficiency were associated with limb loss (P
 .05). Renal failure with dialysis dependence (P  .01)
and poor tibial runoff (P .05) was associated with failure
of primary patency and limb loss. Kaplan-Meier life-table
analysis demonstrated primary patency (all patients) and
limb salvage (CLI patients) probabilities at 12months were
43.8%  0.1% and 55.0%  0.2%, respectively (Figs 1 and
2). Nine of the 17 patients who failed primary patency went
on to a secondary revascularization (repeat endovascular
procedures, 2; surgical bypass, 7).
DISCUSSION
Recently, many authors have suggested that the endo-
vascular technique should surpass surgical bypass as the
first-line therapy for chronic lower extremity ischemia.8-10
The interventional literature has consistently supported this
first-line angioplasty approach, but the surgical literature
remains, as expected, guarded at times. The principle argu-
ments against a primary endovascular approach to infrain-
guinal occlusive disease is purportedly the higher patency
rates realized with surgical bypass grafts and the possibility
of converting a relatively simple open revascularization to a
Table III. Perioperative outcome after laser atherectomy
No. or mean %
Technical success 35 88
Hemodynamic success* 30 75
Change in ABI (mean  SE) 0.26  0.03
Adverse event 13 33
Death (30 day) 2 5
Vessel perforation 2 5
Hematoma or bleeding 1 3
Dissection (nonflow limiting) 5 13
Arteriovenous fistula 1 3
False aneurysm 1 3
Other 1 3
ABI, Ankle-brachial index; SE, standard error.
*Defined as an increase in ABI 0.1.Table I. Patient characteristics
Characteristic* No. or mean % or range
Demographics
Patients 40 100
Age, years 67.9  2.1 (43-93)
Female gender 21 52
Indication–Rutherford
category
3–Severe claudication 14 35
4–Ischemic rest pain 11 28
5–Minor tissue loss 15 38
Clinical
Diabetes mellitus 22 55
Type I 2 5
Type II 20 50
Hypertension 37 93
Hyperlipidemia 23 58
Tobacco (any history) 27 68
Coronary artery disease 18 45
Serum creatinine (mg/dL) 1.1  0.08
Dialysis 5 13
Medical management
Aspirin 31 78
Clopidogrel 26 65
Warfarin 7 18
Lipid therapy 19 48
Follow-up, mean (days) 461  49 (17-1050)Table II. Characteristics of 47 lesions treated by laser
atherectomy in 40 patients
Characteristic No. %
Femoropopliteal segment
Lesions, n 34
Occluded, n 14 41
TASC A 3 9
TASC B 17 50
TASC C 10 30
TASC D 4 12
Infrapopliteal segment
Lesions, n 13
Occluded, n 7 54
TASC A 1 8
TASC B 3 23
TASC C 4 31
TASC D 5 39
Adjunctive procedures
None 6 15
PTA 30 75
Stent 5 13
Hybrid
Open/endovascular
3 8
Tibial runoff
0 5 13
1 20 50
2 7 18
3 8 20
TASC, TransAtlantic Inter-Society Consensus; PTA, percutaneous translu-
more complex one. This argument is offset by the reported
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significant morbidity associated with lower extremity by-
pass.11,12 We have maintained an aggressive stance towards
endovascular-based revascularization, primarily because of
the morbidity associated with surgical revascularization in
this high-risk, underserved patient population.
This study used a catheter-based excimer laser atherec-
tomy system. The catheter contains a flexible fiberoptic
channel that allows the remote delivery of 308-nm wave-
length energy to the target lesion. A unique property of this
ultraviolet excimer laser is that it selectively ablates athero-
sclerotic plaque and thrombus.13,14 The goal of laser-based
endovascular therapy is to primarily treat appropriate le-
sions and convert more complex angiographic scenarios to
those more amenable to angioplasty. In addition, the laser
catheter assists in traversing total occlusions with the avoid-
ance of subintimal techniques.
Laird et al3 described the contemporary trial justifying
the use of a laser-based revascularization strategy. The
LACI was a prospective trial that enrolled 145 patients
deemed to be poor surgical candidates. Laser-assisted re-
vascularization achieved a high initial technical success rate
Table IV. Univariate analysis of patient and anatomic vari
salvage (patients with critical limb ischemia)
Variables*
Primary patency,
n 
Yes
Patient variables
Number 23
Age, years 69.9  2.8
Female gender 13(61)
Critical limb ischemia 15(65)
Diabetes 11(47)
Hypertension 22(96)
Hyperlipidemia 11(48)
Tobacco 15(65)
Coronary disease 12(52)
Renal insufficiency‡ 4(17)
Dialysis 0(0)
Medical management
Aspirin 18(78)
Clopidogrel 14(61)
Warfarin 5(22)
Lipid therapy 9(39)
Anatomic characteristics
Femoropopliteal–Any 19(82)
Femoropopliteal–TASC C or D 6(26)
Infrapopliteal–Any 8(35)
Infrapopliteal–TASC C or D 5(22)
Tibial runoff 1.7  0.2
Runoff 1 vessel 12(52)
Initial technical success 20(87)
Initial hemodynamic success 11(48)
CLI, Critical limb ischemia  Rutherford category 3; TASC, TransAtlant
*Categoric values presented as number (%); continuous variables as mean 
†P  .05.
‡Serum creatinine 1.5 mg/dL.
§P  .01.and a 6-month limb salvage rate of 93%. These high initialsuccess rates were in the face of mostly TASC C and D
lesions. Data were only collected to the 6-month trial end
point. The principle critiques of this study include its
nonrandomized design and small sample size for a multi-
center study. Nonetheless, one can conclude from the
LACI trial that laser-assisted angioplasty can be used across
a wide range of complex anatomic lesions with a high
technical success rate and admirable short-term success
rates. These data were echoed in a subsequent European
study citing 6-month limb salvage 90%.4
Advocates of a primary endovascular approach to lower
extremity ischemia cite procedural morbidity and patient
preference toward a more minimally invasive approach as
the primary driving forces. Indeed, the morbidity of surgi-
cal lower extremity revascularization can be significant. A
recent study from Conte et al15 demonstrated a 30-day
morbidity of 17.6% and mortality of 2.7% after lower
extremity bypass. In fact, total morbidity, including minor
events, is undoubtedly much higher for these patients.16
The study presented here found a total complication
rate of 33%; however, most of these were anatomic subop-
timal results and did not alter the length of stay or short-
associated with primary patency (all patients) and limb
) (all patients, Limb salvage, n (%) (CLI patients,
n  26)
No Yes No
17 19 7
65.2  3.1 64.1  3.1 49.2  4.9
8(47) 11(58) 3(42)
14(82) N/A N/A
7(41) 11(58) 6(86)†
15(88) 17(89) 7(100)
12(71%) 12(63) 6(86)
12(71) 11(58) 5(71)
6(35) 9(47) 4(57)
7(41) 4(21) 5(71)†
5(29)§ 1(5) 4(57)§
13(76) 15(79) 6(86)
12(71) 10(53) 5(71)
2(12) 5(26) 1(14)
19(59) 11(58) 5(57)
15(88) 11(58) 3(43)
8(47) 6(31) 1(14)
5(29) 9(47) 4(57)
4(24) 6(32) 3(43)
1.1  0.2† 0.9  0.2 0.3  0.2†
3(18)† 6(31) 0(0)†
15(88) 17(89) 6(86)
7(41) 7(37) 3(43)
r-Society Consensus; N/A, not applicable.
ard error.ables
n (%
40)
ic Inte
standterm morbidity to the patient. Our practice includes a high
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These patients are often at higher surgical risk, because they
tend to present with poorly managed risk factors and ad-
vanced ischemic disease.17 In the face of these data, a
minimally invasive approach is justified in higher-risk pa-
Fig 1. Kaplan-Meier curve shows primary patency of revascular-
ization of 40 patients undergoing laser atherectomy. Renal, Renal
dysfunction (serum creatinine1.5 mg/dL);Runoff, patent tibial
runoff vessels 2; DM, diabetes mellitus.
Fig 2. Kaplan-Meier curve for limb salvage of 26 patients with
critical limb ischemia (CLI), defined as Rutherford category 3,
undergoing laser atherectomy. Renal, Renal dysfunction (serum
creatinine 1.5 mg/dL); Runoff, patent tibial runoff vessels 2;
DM, diabetes mellitus.tients, especially those without a suitable conduit.Primary patency was defined as continued hemody-
namic improvement in the setting of clinical improvement.
Limb salvage was defined as freedom from major amputa-
tion ipsilateral to the site of laser intervention. Within the
confines of these definitions, the 12-month primary pa-
tency and limb salvage rates were 44% and 55%, respec-
tively, by life-table analysis (Figs 1 and 2). This number
contrasts sharply with the aforementioned LACI trials.3,4
These divergent results have several possible explanations:
1. This study is a retrospective review, subject to all the
common critiques.
2. Although this was one of the larger single-institution
excimer laser series for lower extremity revasculariza-
tion, the number of patients enrolled was relatively
small, and therefore treatment failure in a small number
of patients has a major impact on outcome. Divergence
in real-world clinical outcomes and those achieved on
clinical trials is well described throughout a variety of
clinical disciplines.18
3. The series we have presented has a significant number of
patients with renal insufficiency and dialysis depen-
dence. These variables were not specifically reported in
the above-cited multicenter trials; thus, comparison is
difficult. Our data do not reproduce the impressive
results of the LACI trials, but instead coincide with
earlier excimer laser results described in the literature.19
In our study, diabetes was found to be a significant
factor associated with limb loss but not with initial treat-
ment failure. Diabetes has previously been described as an
independent risk factor for poor outcomes and limb loss by
other authors as well.20-24 An important factor in this
correlation is that this deleterious role of diabetes mellitus
can be minimized with appropriate glycemic control.25,26
Macrovascular andmicrovascular circulation are both influ-
enced by the presence of diabetes and the level of glycemic
control. Using glycosylated hemoglobin (HbA1c) as a sur-
rogate, the vascular surgeon can readily monitor and opti-
mize glycemic control in the diabetic patient with lower
extremity ischemia. Accordingly, our patients with diabetes
mellitus undergoing laser atherectomy all received appro-
priate periprocedural glucose control, and appropriate re-
ferrals were made for those patients with evidence of poor
historic blood glucose control.
The other major clinical variable identified in this anal-
ysis was renal dysfunction. This study identified dialysis
dependence as a risk factor for both revascularization failure
and limb loss. In addition, renal insufficiency was associated
with limb loss (Table IV). The negative impact of poor
renal function was profound, with all dialysis patients re-
quiring a second attempt at revascularization 6 months
and all but one dialysis patient undergoing major amputa-
tion. Like diabetes, renal dysfunction has been well docu-
mented as an independent risk factor for short-term and
long-term outcomes in the patient undergoing both open
and percutaneous lower extremity revascularization.12,27,28
The significant risk of cardiovascular complications in this
patient population makes a minimally invasive approach
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revascularization outcomes described in this study and
others noted above.
An important observation in this study is that retro-
spective TASC classification was not a predictor of revascu-
larization success or limb salvage; however, tibial runoff was
a correlate of both durability and limb salvage. The discor-
dance between TASC classification and outcome in this
series has several possible explanations:
First, although lesion length and resultant TASC clas-
sification has been a widely accepted method for predicting
outcome after lower extremity revascularization, there are
reports in the literature of equivalent outcomes regardless
of anatomic characteristics.6,9,29
Second, and more probable, is the significant risk of a
type II error because of the sample size in this study. The
possibility of a type II error is supported by the observation
that, while statistically not significant, there was a trend
towards failure of primary revascularization in those pa-
tients with TASCC andD lesions. As expected, poor runoff
was a marker for both failure and limb loss, as has been well
described in other endovascular revascularization series.30
Of importance is that the primary patency rate pre-
sented in this study is similar or worse than that in other
reports. The 1-year primary patency rate of 44% is poor
compared with surgical revascularization and marginal
compared with other endoluminal therapies. In our own
experience, 6-month and 12-month patency of femoro-
popliteal intervention with and without concurrent tibial
intervention is 60% and 53%, respectively (unpublished
data). This is similar to the cited reports and suggests that
there is no mid-term or long-term advantage to laser-
assisted revascularization compared with any other endolu-
minal approach. Use of the laser allowed for an improved
technical success rate, which approached a 90%; however,
this high immediate success rate did not translate into
long-term success. This likely represents a case-selection
bias, because the laser was not used on cases where a
guidewire could be easily passed to the distal circulation.
Without a randomized study, this question is difficult to
address, but admittedly the data are not positive.
Limitations of this study have largely been discussed
and include the retrospective nature and relatively small
sample size. Also, because of the small sample size, patients
with severe claudication (Rutherford category 3) were in-
cluded with patients presenting with CLI. The analysis
failed to demonstrate a difference in these two groups with
respect to primary patency. One could conclude that these
data demonstrate that anatomic factors, not the indication
for revascularization, are the more important determinants
for outcome; however, the small number of patients in each
group makes this study underpowered to answer that ques-
tion. Furthermore, this same size constraint makes it im-
possible to answer this and other questions with multivar-
iate statistical methods. In addition, single-institution series
are often biased toward a particular patient demographic or
practice pattern. These data do represent a real-world ap-
plication of excimer laser technology for lower extremityrevascularization, however, and overall results tend to mir-
ror other contemporary percutaneous revascularization re-
ports.9,19,31
CONCLUSION
These data demonstrate that laser-assisted revascular-
ization of the infrainguinal circulation is technically feasible
outside the confines of a clinical trial. The initial technical
success rate approached 90%, and most lesions were treated
with the avoidance of stenting. Those patients with diabe-
tes and renal dysfunction faired poorly with respect to
durability and ultimate limb salvage, however. Because of
these poor outcomes, it is difficult to recommend laser
revascularization as primary therapy for these patients, and
therefore, surgical revascularization should be strongly
considered, especially in low-risk or intermediate-risk pa-
tients. When undertaking laser atherectomy in higher-risk
patients, expectations should be lowered and patients
counseled appropriately. Finally, the dismal results in dialysis-
dependent patients with CLI require careful consideration
and argue against laser-assisted revascularization for most.
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TransAtlantic Inter-Society Consensus (TASC) classification for femoropopliteal and infrapopliteal lesions
TASC classification Characteristics
Femoropopliteal
A A single stenosis 3 cm long, not at the origin of the superficial femoral or distal popliteal artery
B A single stenosis or occlusion 3 to 5 cm long not involving the distal popliteal, or multiple
stenoses or occlusions, each 3 cm long
C A single stenosis or occlusion 5 cm long, or multiple lesions each 3 to 5 cm long
D Complete occlusion of the femoral arteries, or complete occlusion of the popliteal artery and
proximal trifurcation
Infrapopliteal
A A single stenosis 1 cm long of the tibial or peroneal vessels
B Multiple focal stenosis 1 cm long, one or two stenoses 1 cm involving the trifurcation, or
short stenosis of the tibial arteries in conjunction with femoral angioplasty
C Stenosis 1 to 4 cm long or occlusion 1 to 2 cm long of the tibial arteries, or extensive stenosis of
the trifurcation
D Occlusion 2 cm long or diffuse infrapopliteal lesions
